GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » EPS (Diluted)

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) EPS (Diluted) : $-0.74 (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals EPS (Diluted)?

60 Degrees Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.44. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.74.

60 Degrees Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $-0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.74.

60 Degrees Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-0.42. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49.

During the past 3 years, the average EPS without NRIGrowth Rate was -1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, 60 Degrees Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -1.40% per year. The lowest was -1.40% per year. And the median was -1.40% per year.


60 Degrees Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals EPS (Diluted) Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.55 -0.76 -1.11 -0.99

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.30 -0.47 -0.60 0.77 -0.44

Competitive Comparison of 60 Degrees Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's PE Ratio falls into.



60 Degrees Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

60 Degrees Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.766-0)/3.960
=-0.95

60 Degrees Pharmaceuticals's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.012-0)/5.807
=-0.35

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


60 Degrees Pharmaceuticals  (NAS:SXTP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


60 Degrees Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.
Executives
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines